Sakar Healthcare Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.9K Cr
Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic). Oncology segment expected to grow 60%-70% year-on-year in FY’27, building on ~30% growth in FY’26. - Oncology revenues forecasted to cross INR 200 crores in FY’27 from approx.
From Sakar Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 3 Sept 2026.
Price
₹1,002
Market Cap
₹1.9K Cr
P/E Ratio
54.0
How does Sakar Healthcare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sakar Healthcare Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹71 Cr, net profit ₹11 Cr.
Full financials →📊 Revenue & Sales Performance
- →Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic).
- →For FY’27, anticipated oncology revenue growth is 60% to 70% year-on-year, potentially crossing INR200 crores.
- →Significant ramp-up expected due to 100+ marketing authorization submissions pending approval within 12 months and 200 dossiers with partners.
- →Tech transfer projects with major pharma companies, including Accord/Intas, expected to start contributing from FY’27 onwards.
- →Imatinib technical transfer with Accord will commence end March FY’26; other tech transfer molecules to follow.
- →Partnerships in Europe (Torrent UK, Heumann Germany, etc.) poised to drive expansion.
- →Capex for capacity expansion completed; future capex expected to be limited to maintenance only.
See what Sakar Healthcare Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
- →For FY’26, Sakar Healthcare incurred a capex of approximately INR 39 crores till nine months, primarily towards plant and machinery setups and utilities as per revised capacity requirements.
- →The major planned capex has been completed, and no significant further capex is expected for FY’27.
- →Maintenance capex is estimated at around INR 65 lakhs per quarter, related to repairs and upkeep of existing plants.
- →The company has completed the setup required for oncology and other product capacities, implying current investments focus on sustaining operations rather than expansion.
- →Backward integration initiatives, like obtaining CEP approvals for APIs, are underway to improve supply reliability and margins, suggesting strategic investment in regulatory compliance and in-house capabilities.
See what Sakar Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
- →The order book currently shows that Sakar Healthcare is on track to achieve over 40% growth year-over-year for FY’26.
- →Oncology revenues are driving overall revenue growth with a significant ramp-up expected in the coming quarters.
- →The company expects most tech transfer revenues to start accruing from FY’27 onwards, including from the Imatinib agreement with Accord/Intas starting end of March.
- →There are 100+ marketing authorization submissions pending approval expected within the next 12 months, which will further increase sales.
- →Additionally, 200 dossiers are with partners in different countries awaiting submission, supporting future growth.
- →Technology transfer projects with five large pharmaceutical companies have potential revenues in the range of INR50 to INR100 crores from currently managed products.
- →Order fulfillment is typically linked to advance payments from international markets before dispatch.
Key Metrics
Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Sakar Healthcare Ltd Q3 FY26 results?
Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic). Oncology segment expected to grow 60%-70% year-on-year in FY’27, building on ~30% growth in FY’26. - Oncology revenues forecasted to cross INR 200 crores in FY’27 from approx.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.0 with a market cap of ₹1,948 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
For FY’26, Sakar Healthcare incurred a capex of approximately INR 39 crores till nine months, primarily towards plant and machinery setups and utilities as per revised capacity requirements.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.